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Abstract
Suicidal behaviors are frequent in mood disorders patients but only a subset of them ever complete suicide. Understanding
predisposing factors for suicidal behaviors in high risk populations is of major importance for the prevention and treatment
of suicidal behaviors. The objective of this project was to investigate gene expression changes associated with suicide in
brains of mood disorder patients by microarrays (Affymetrix HG-U133 Plus2.0) in the dorsolateral prefrontal cortex (DLPFC: 6
Non-suicides, 15 suicides), the anterior cingulate cortex (ACC: 6NS, 9S) and the nucleus accumbens (NAcc: 8NS, 13S).
ANCOVA was used to control for age, gender, pH and RNA degradation, with P#0.01 and fold change61.25 as criteria for
significance. Pathway analysis revealed serotonergic signaling alterations in the DLPFC and glucocorticoid signaling
alterations in the ACC and NAcc. The gene with the lowest p-value in the DLPFC was the 5-HT2A gene, previously associated
both with suicide and mood disorders. In the ACC 6 metallothionein genes were down-regulated in suicide (MT1E, MT1F,
MT1G, MT1H, MT1X, MT2A) and three were down-regulated in the NAcc (MT1F, MT1G, MT1H). Differential expression of
selected genes was confirmed by qPCR, we confirmed the 5-HT2A alterations and the global down-regulation of members
of the metallothionein subfamilies MT 1 and 2 in suicide completers. MTs 1 and 2 are neuro-protective following stress and
glucocorticoid stimulations, suggesting that in suicide victims neuroprotective response to stress and cortisol may be
diminished. Our results thus suggest that suicide-specific expression changes in mood disorders involve both
glucocorticoids regulated metallothioneins and serotonergic signaling in different regions of the brain.
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Introduction
Suicide is one of the leading causes of death in the world
particularly for young males and projections of global mortality
indicate that suicide rates are rising [1] and will remain a leading
cause of injury and death worldwide [2]. The number of suicides is
approximately 1 million per year in the world [3]. In the United
States suicide is the eleventh leading cause of death for all ages and
the third leading cause among adolescents [4]. One third of those
suicides visited a health care professional within a week before
committing suicide [4]. This suggests that better methods are
needed in assessment of suicidal intent in at risk populations.
Mood disorders (major depressive disorder (MDD) and bipolar
disorder (BD)) constitute prominent risk factors for suicide [5–7].
Accordingly, lifetime risk for suicide in mood disorders patients is
particularly high when compared to the general population [8–
12]. In BD patients suicide attempts are specifically associated with
depressive episodes rather than manic episodes [13]. Despite
current advances in the understanding of suicide predisposing
factors, existing diagnostic algorithms are inadequate and the
identification of individuals at high risk for suicide is frequently
missed [14].
Suicide and suicidal behaviors have been consistently linked to
monoaminergic (serotonin, norepinephrine and dopamine) neu-
rotransmission alterations [15–17] and to alterations in the
hypothalamic-pituitary-adrenal (HPA) axis [18–20]. Postmortem
receptor/transporter binding studies have also confirmed alter-
ations in the number and affinity of monoaminergic receptors in
the brains of suicides [17,21]. Interestingly, both serotonergic
neurotransmission imbalance and HPA axis over-activity are
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suicide [22]. Recent evidence has shown that childhood abuse
alters HPA stress responses and increases the risk of suicide
through epigenetic regulation of glucocorticoid receptor expres-
sion underlining the role played by the HPA-stress response in the
susceptibility to suicide [23].
Recently, microarray technology has been used to investigate in
post-mortem brain global gene expression alterations associated
with mood disorders and suicide compared to psychiatrically
normal controls [24]. A number of studies specifically explored
gene expression alterations in post-mortem brains of suicides
versus control subjects in prefrontal regions [25–30] and in the
limbic system [31,32] with very few replicated results due probably
to methodological and demographic differences in the samples.
These studies focused mainly on the investigation of genes
differentially expressed between psychiatric cases that committed
suicide and controls, but did not compare the psychiatric patients
who commit suicide from those who do not. To our knowledge,
only two recent articles investigated suicide specific changes in the
brain by comparing suicide versus non-suicide psychiatric patients.
Garbett et al. observed a prefrontal cortical down-regulation of the
HTR2A receptor in subjects with schizophrenia who committed
suicide using Affymetrix arrays [33]. Also, Kim et al. (2007)
reanalyzed a large microarray data set to investigate gene
expression in major depression and schizophrenic patients who
did and did not commit suicide, in the prefrontal cortex (BA10/46)
[30]. They found alterations on 2 genes across diagnoses, PLSCR4
(phospholipid scramblase 4) and EMX2 (empty spiracles homolog
2 (Drosophila)) and several members of the metallothionein
subfamily 1 (MT1E, MT1X, MT1M, MT1G, MT1H, MT1F)
as being specifically down-regulated among the schizophrenics
who committed suicide [30].
Mental disorders and particularly mood disorders contribute
significantly but not exclusively to the risk of suicide. Determining
the expression changes in the brain that differentiate suicide from
non-suicide mood disorder brains should help identify the genes
specifically involved in suicide. In this study, we investigated a
cohort of mood disorder subjects (BD and MDD) for gene
expression changes specifically associated with suicide in the
DLPFC, ACC, and NAcc, three regions commonly associated
with suicidal behavior alterations, mood, control of impulses,
motivation, reward and pleasure, behaviors know to be altered in
mood disorders.
Methods
Subjects
Brain samples were obtained at the University of California,
Irvine/Davis Brain Repository through a uniform process
approved by the Institutional Review Board. Written informed
consent was obtained from the next-of-kin of the deceased. All
subjects went through an extensive review of multiple sources of
information including the medical examiner’s conclusions, coro-
ner’s investigation, medical and psychiatric records, toxicology
results, and interviews of the decedents’ next-of-kin, in order to
rule out as much as possible any neurological disorder.
Additionally, a neuropathological examination of each brain was
conducted in order to exclude cases with cerebrovascular disease
(infarcts or hemorrhages), subdural hematoma, or other significant
pathological features. Our psychological autopsy protocol is based
largely on procedures validated by Kelly and Mann [34]. Details
of death are evaluated in order to assign an Agonal Factor Score to
each subject in accordance with previous guidelines hardy [35,36].
Previous work consistently showed an association between agonal
factors and tissue quality [37–40]. Brains are initially screened for
agonal factors at the time of consent in order to exclude brains
with factors potentially affecting nucleic acids and proteins.
Subjects with history of drugs or alcohol dependence were also
excluded from the present sample. Non-suicide subjects, including
mood disorder subjects and normal controls, died rapidly from
either cardiac related events or motor-vehicle accidents.
The human brain dissection and freezing protocol is described
in detail elsewhere [41]. Briefly, the whole brain is first inspected
and photographed before the brainstem and cerebellum are
separated from the cerebrum. The cerebrum is coronally sliced
from anterior to posterior and slices are photographed, labeled,
and bagged before being frozen. Small 5 cm squares are dissected
for both pH and RNA quality measurements. Freezing is done by
placing the bagged slices between super-cooled aluminum plates,
then in a pre-cooled freezing rack before putting the whole rack in
a 2140uC freezer for a minimum of 10 minutes. The brains are
stored in 280uC freezers until dissected and processed for
extractions. The brain regions were dissected on dry ice from
the left hemisphere of frozen tissue according to visible landmarks
near the regions of interest under the direction of Dr E. G. Jones.
Grey matter punches were taken from the cortical regions and
from the middle of NAcc region.
Grey matter brain samples (25 mg) were used to extract total
RNA with the Trizol method (Invitrogen, Carlsbad, CA), followed
by a cleaning up using a silica based mini-spin column (Qiagen
RNeasy Mini Kit, Valencia, CA). RNA integrity was evaluated
using 18S and 28S ratios and RNA integrity numbers (RIN) using
the 2100 Agilent Bioanalyzer (Santa Clara, CA). All subjects were
clinically characterized with the psychological autopsy method and
died suddenly without prolonged agonal state.
Microarray Analysis
Cel files from Affymetrix HG-U133 Plus2.0 chips were
processed using the RMA algorithm. Statistical analysis was
performed using Partek (St. Louis, MO). An ANOVA model was
used to identify the differentially expressed genes between the non
suicides and the suicides in a sample of mood disorder patients
controlling for age, gender, RIN, and pH. Additionally, the
AffyRNAdeg function was used to generate 39/59 slopes indicating
RNA degradation and used as covariate in the ANOVA model
[42]. Genes were considered as differentially expressed if they had
a P-value of less than 0.01 and a fold change of 61.25. Pathway
analysis was performed using Ingenuity (Redwood City, CA) and
the differentially expressed probe sets in each region.
Outlier detection was conducted in order to exclude problem-
atic arrays using a combination of principal component analysis
(PCA), and RNAdeg Slopes. In the DLPFC, 21 subjects were
analyzed by microarrays, 15 suicides (3 females/12 males) and 6
non-suicides (2 females/4 males). In the ACC, a total of 15
subjects were included in the microarray analysis, 9 suicides
(3 females/6 males) and 6 non-suicides (3 females/3 males). In the
NAcc a total of 21 subjects were analyzed by microarrays,
13 suicides (3 females/10 males) and 8 non-suicides (2 females/
6 males). For the microarray experiment sample (cohort 1),
demographic and physiological variables used for the ANOVA
model and to assess the RNA quality (age, pH, PMI or RIN
numbers) can be found in Table 1 for the group averages and
standard deviation and Table S1 for the detailed information.
The entire dataset has been deposited to the Gene Expression
Omnibus (GEO) with the Accession Number GSE6306 (Table
S6).
Gene Expression in Suicide Brains
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Confirmation of a subset of genes was done was done in an
extended cohort including also normal controls by quantitative
real-time polymerase chain reaction (qPCR) using the SYBR
Green chemistry. Normalization of the qPCR results was
performed using the geNorm method developed by Vandesompele
et al. [43], this method consists on a factor calculation
normalization based on the geometric mean of multiple endog-
enous control genes, in this case we used CAMK2A and SDHA.
Samples were run in triplicate and confirmation of the results was
determined by ANOVA controlling for age, pH, and diagnosis.
Primers were designed to amplify regions close to the correspond-
ing target sequences in the microarray experiments and spanning
two exons in order to only amplify mRNA (primers are available
on request). Experiments were performed in a 384 well plate in a
total volume of 10 ml on a 7900 HT real time sequence detector
(Applied Biosystems, Foster City, CA). The qPCR confirmation
cohort (cohort 2) also included normal controls and showed no
differences in terms of age, pH, gender or PMI between the groups
(Table 2 and Table S2).
Results
No significant differences between the suicide and non-suicide
groups were observed for the major demographic variables such as
pH, age, RIN, PMI and RNAdeg slope (Table 1 and Table S1).
In order to control for possible confounding effects, demographic
variables, such as diagnosis and age, and RNA quality measures
(RIN and slope) were used as covariates.
A total of 161 genes were found to be differentially expressed in
the DLPFC (Table S3). The most statistically significant gene in
this region was the 5-HT2A gene (P=0.00022, FC=21.28),
previously identified as being implicated in both mood disorders
and in suicide consistently. The decrease of 5-HT2A expression in
the suicide group was confirmed by qPCR (data not shown).
Enrichment of canonical pathways analysis using Ingenuity
confirmed that the serotonin receptor signaling pathway was
altered in suicide brain tissue (Fig. 1 a). Another gene of interest
previously shown to be involved in suicide [44] and that was
altered in the DLPFC was the adenylate cyclase 1 (brain) (ADCY1)
gene that codes for a brain specific form of adenylate cyclase
responsible of the production of the second messenger cyclic AMP,
ADCY was significantly down-regulated in suicide versus non-
suicide patients. Finally, period homolog 1 (PER1), a major
component of the circadian rhythm system, was also down-
regulated in suicides compared to non-suicides. Clock genes have
been in the past associated with mood disorders [45] but not
specifically with suicide. In summary, the DLPFC data shows it is
possible to detect significant expression alterations in human brain
areas between suicides and non-suicides brains and confirms the
involvement of serotonergic and second messenger system
alterations in suicide.
In the ACC, 139 annotated probe sets were differentially
expressed between the suicides and non-suicides cases (Table S4).
Of these, eight probe sets corresponded to seven metallothionein
family members (MT1E, MT1M, MT1F, MT1G, MT1H,
MT1X, MT2A), located as a cluster on chromosome 16q13
(Table 3). All these probe sets were significantly down-regulated in
suicide victims with fold changes varying from 21.46 to 21.83.
Pathway analysis conducted using Ingenuity on the 139 differen-
tially expressed probe sets revealed that the most over represented
pathway was glucocorticoid receptor signaling (Fig. 1 b). Further
exploration of the probe sets altered in the glucocorticoids receptor
signaling pathway revealed a global down-regulation of metallo-
Table 1. Demographic and physiological details for the subjects included in the microarray gene expression study sample
(cohort 1).
DLPFC ACC NAcc
Suicide (n=15) NS (n=6) Suicide (n=9) NS (n=6) Suicide (n=13) NS (n=8)
Age (Mean±SD) 44614 42617 43695 3 610 43695 4 68
pH (Mean±SD) 6.860.3 6.960.4 6.960.3 6.760.3 6.960.3 6.860.2
PMI (Mean±SD) 2564.2 2368.3 2465.0 2565.0 2464.7 2566.6
Slope (Mean±SD) 3.360.6 2.960.3 3.660.3 4.060.5 3.060.2 2.960.4
RIN (Mean±SD) 7.960.5 7.960.6 8.060.4 8.060.3 8.160.4 8.060.5
Mean6standard deviation values (SD) are presented. The slope was calculated using the AffyRNAdeg function. DLPFC: dorsolateral prefrontal cortex, ACC: anterior
cingulate cortex, NAcc: nucleus accumbens.
doi:10.1371/journal.pone.0035367.t001
Table 2. Demographic and physiological details for the subjects included in the qPCR validation sample (cohort 2).
DLPFC ACC NAcc
Suicide
(n=20) NS (n=11)
Control
(n=27)
Suicide
(n=10) NS (n=7)
Controls
(n=18)
Suicide
(n=13) NS (n=7)
Control
(n=10)
Age (Mean±SD) 44612 52611 50615 43611 54694 9 614 46694 9 694 1 611
pH (Mean±SD) 6.960.2 6.960.2 6.960.3 7.060.2 6.960.2 7.060.2 6.960.2 6.960.2 6.960.2
PMI (Mean± SD) 26642 4 662 0 672 4 652 6 652 0 652 5 652 4 662 1 65
RIN (Mean ± SD) 7.960.5 7.860.7 7.860.6 8.2618 . 3 618 . 0 61N A N A N A
Mean6standard deviation values (SD) are presented. DLPFC: dorsolateral prefrontal cortex, ACC: anterior cingulate cortex, NAcc: nucleus accumbens, NA: not available.
doi:10.1371/journal.pone.0035367.t002
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expression levels of all the metallothionein genes revealed that
most of the genes in subfamilies 1 and 2 where down-regulated in
the ACC, including pseudogenes co-localized in 16q13 (Fig. 2).
Interestingly, the brain specific MT3 gene was highly expressed,
but showed no differences in gene expression like subfamilies 1
and 2.
In the NAcc, 146 probe sets were differentially expressed
between suicides and non-suicides (Table S5). Three metallo-
thionein genes were also down-regulated in the NACC (MT1F,
MT1G, MT1H) among the suicide victims and like in the ACC
several others were also down-regulated although at a P,0.05
level. IPA did not reveal any canonical pathway as being over-
represented, as opposed to the ACC (Fig. 1 c), only three MT
genes passed the significance criteria. However, 7 probe sets in
total were differentially expressed at the 0.05 level confirming the
overall dysregulation in this family of genes (Fig. 2). The Wolfram
syndrome gene (WFS1), previously associated with psychiatric
disorders and suicide [46–48], was also down-regulated among the
suicide victims in the NACC.
Confirmation of Results by qPCR
Group averages for demographic and physiological variables for
the subjects (cohort 2) included in the confirmation experiments
per region can be seen in Table 2 and for subjects in cohort 2 used
in this analysis can be seen in Table 2 and detailed demographic
data in table S2. All the subjects used the validation cohort had
high pH (mean=6.9) and RIN values (mean=8), and an average
the PMI of 23 hours (8.5 to 37 hours). Metallotionein gene
expression down-regulation in both the ACC and NACC was
confirmed by qPCR for all the functional variants in sub-families 1
and 2 known to be expressed in the brain (MT1E, MT1F, MT1G,
MT1H, MT1X, MT2A). In summary, the pattern of metallothio-
nein expression was confirmed to be lower in the suicides
compared to the non-suicides in both the ACC and NACC for
all the genes examined (Figs. 3 and 4). When compared to
normal controls, metallothionein levels tended to be elevated in
the non-suicide mood disorder group, especially in the NAcc,
while lower specifically in the suicide group.
Discussion
A gene expression survey by microarrays in three brain regions
(DLPFC, NAcc and ACC) revealed alterations in the serotonergic
and second messenger systems in the DLPFC and a consistent
down-regulation of several members of the metallothionein
subfamilies 1 and 2 genes in the NAcc and ACC in mood
disorder suicides. Our strategy consisted on using high quality
brains (short PMI, high pH, high RIN) with no history of drug
dependence, as well as the development of a general linear model
in which factors known to influence RNA quality and expression
were taken into account when exploring the suicide specific
expression changes. This is to our knowledge the first study
investigating suicide specific changes in mood disorders in three
highly relevant areas as they are involved in the control of impulses
and in mood disorders (DLPFC, ACC) and in motivation-reward
mechanisms (NAcc).
We studied gene expression changes in the DLPFC, an area
previously associated with both mood disorders, control of
impulses and suicide. Interestingly, the most statistically significant
gene differentially expressed in suicide victims was the 5-HT2A
serotonergic receptor, with a1.28 fold-change reduction in mood
disorder subjects that committed suicide versus non-suicide mood
disorder subjects. Genetic association studies have often shown
that mutations in the 5-HT2A receptor are associated with mood
disorders and suicide [49], as well as with the response to
antidepressants [50]. Additionally, gene expression post-mortem
studies have revealed alterations 5-HT2Areceptor levels in mood
disorder subject suicides when compared to controls. However the
direction of the alterations in 5-HT2A is controversial, with some
reports showing elevations in the 5-HT2A binding and expression
[51–55] while others showed reduced levels or no differences [56–
58]. Recently, a well designed study including matched suicides
and controls also confirmed the absence of changes in 5-HT2
binding but reported a decrease in neuronal densities in the
prefrontal cortex in a sample of predominantly major depressed
suicides [59]. In another recent study designed to investigate 5-
HT2A levels in major depression, Shelton et al. reported an
increase in 5-HT2A expression in major depression subjects, but
reported no differences when comparing suicides versus non-
suicide subjects [55]. In this study, we aimed to investigate suicide
specific changes in mood disorder patients and observed a
significant decrease in 5-HT2A levels in suicide which can at
least partially explain previous discordant findings when compar-
ing mood disorder to controls or suicides to controls. The
reduction in 5-HT2A levels is also in concordance with another
study comparing suicide versus non-suicide schizophrenia subjects
using also Affymetrix microarrays [33], suggesting that this
reduction in 5-HT2A levels might be involved in suicide
irrespective of the diagnosis. We also observed decreased
expression in suicide group of the brain specific ADCY1, a brain
specific form of adenylate cyclase, suggesting altered neurotrans-
mission and cyclic AMP signaling in suicide and confirms previous
observations pointing to cAMP signaling alterations in suicide and
mood disorders [60–63] and in animal models of depression [64].
Both serotonergic alterations and second messenger systems
underline global neurotransmission alterations in the DLPFC that
seem to play a role in the predisposition to commit suicide.
In both the ACC and NAcc decreased expression was observed
in gene members of two subfamilies (1 and 2) of the
metallothionein super family in the suicides versus the non-
Figure 1. Canonical pathway enrichment analysis using Ingenuity. A In the DLPFC. B In the ACC. C In the NAcc.
doi:10.1371/journal.pone.0035367.g001
Table 3. qPCR Confirmation of decreased expression of
metallothionein subfamilies 1 and 2.
NACC ACC
P-value T P-value T
MT1E 0.09 3.25 0.02 6.36
MT1F 0.02 7.23 0.05 4.14
MT1G 0.01 7.63 0.01 7.67
MT1H 0.01 8.96 0.00 14.19
MT1X 0.03 5.65 0.02 5.99
MT2A 0.03 5.83 0.04 4.72
Significant differences are in bold for one tailed t-test confirming the direction
of the change.
doi:10.1371/journal.pone.0035367.t003
Gene Expression in Suicide Brains
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successfully Metallothioneins are small single chain proteins with a
high content of cysteine residues organized in specific sequences
enabling the formation of thiolate cluster and the binding of
certain metals react to oxidative stress, glucocorticoids and
inflammatory mediators [65]. There are four subfamilies of
metallothioneins proteins in mammals corresponding to types 1
to 4, all metallothionein genes are closely located in chromosome
16q13. MT1 and MT2 are expressed ubiquitously and highly co-
expressed, whereas MT4 is not expressed in the brain and MT3 is
brain specific and expressed mainly in hippocampus amygdala and
cortex in zinc enriched neurons and astrocytes [66]. Consistent
with this, MT3 was also observed to be expressed in the three
brain areas investigated but was not differentially expressed like
MT1 and 2 subfamilies. MT3, unlike MT 1 and 2 is not regulated
by glucocorticoids and stress, which can explain this difference
[67–72].
MT1 and MT2 are not only known to be responsive to several
forms of stress and to glucocorticoids [73], they also play an
important role in neuroprotection [66]. In animal models of stress,
both MT1 and MT2 mRNA were elevated as much as 30-fold
following just 12 h (one cycle) of restraint stress whereas MT3 gene
expression was not altered by stress [74]. The induction occurred
at the transcriptional level and was mediated by the activation of
glucocorticoid receptor [74]. In a stress mouse model, treatment
with a glucocorticoid receptor antagonist (RU 486) prior to
restraint stress inhibited MT induction by at least 50% indication
that at least in part MT induction is under direct control of the
glucocorticoid receptor at the transcriptional levels [75]. Gluco-
corticoids induction of metallothioneins expression is done
through the direct binding of the ligand activated glucocorticoid
receptor to the glucocorticoid response elements (GRE) in the
promoter of MTs [76,77]. Dexamethasone has been shown for
instance to increase significantly the levels of MT and immobi-
lization stress has also been shown to increase selectively MT1 and
MT2 of rat brains [70]. MT1 and 2 play a neuroprotective role
against stress and glucocorticoids elevation by a mechanism of
induced expression of metallothioneins in astrocytes followed by
an extracellular release and internalization by neurons after
binding to the receptor megalin that mediates the transport of
MTs into neurons [78]. Thus, MT1 and 2 sub-families, that play
an important role in neuroprotection from the effects of behavioral
stress and in response to cortisol, are significantly reduced in mood
disorder suicides compared to non-suicides. Interestingly, in
another recent microarray study using Affymetrix Exon 1.0 ST
arrays, Shelton et al. observed and confirmed by qPCR a
decreased expression of MT1M in the BA10 of depressed subjects
compared to controls [79].
Alterations in the hypothalamic-pituitary-adrenal (HPA) axis in
depressive states and suicide have been consistently observed for
more than 40 years [19,80]. It has also been extensively shown
that depressed states are specifically linked to both chronic stress
and elevated cortisol levels relevant of HPA axis hyperactivity in
depression [81]. Many studies have observed higher baseline
cortisol values in young depressed patients [82] and cortisol
hypersecretion in depression [83]. We propose in this study that
decreased levels of MT1 and 2 can result in a higher sensitivity in
suicide completers to the effects of depression-associated cortisol
levels in the brain. If these results are confirmed in a larger
independent cohort, pharmacological agents that increase the
Figure 2. Expression levels of 11 metallothionein probe sets corresponding to 9 gene as measured by microarrays (HG-U133Plus
2.0) in the ACC and NAcc of non-suicide (grey bars) and suicide (black bars) mood disorder subjects. Significant genes/probe sets are
labeled by * (P,0.01) and # (P,0.05) signs.
doi:10.1371/journal.pone.0035367.g002
Gene Expression in Suicide Brains
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transport to neurons by the megalin receptor without necessarily
altering HPA axis activity can be envisioned for the treatment and
prevention of suicide and suicidal behaviors in mood disorder patients.
The effect of known confounding variables in post-mortem
brain gene expression studies (pH, PMI, age, gender, diagnosis
and RNA quality) was controlled by conducting an ANCOVA
using significant variable as covariates. One of the weaknesses of
this study is the relatively small size of the microarray sample.
However, we were able to confirm the observed results in a larger
sample and to explore MT expression in control subjects also by
qPCR in a larger sample in both the ACC and NAcc (Figs. 3 and
4). Another problem observed was the difference in age between
the non-suicides and the suicides in the NAcc and ACC. This was
expected as suicide is particularly prevalent in younger populations
[2,2,7,84] with about 200,000 young people that die every year in
the world by suicide [85]. For that reason, we included age into
the statistical model in order to exclude genes altered by age only.
Ultimately however, MT subfamilies 1 and 2 down-regulation in
suicide mood disorder subjects should be tested in peripheral tissue
such as blood lymphocytes, where they have been shown to be
expressed [86], in order to confirm these results in a clinical
population and to investigate the validity of these changes as a
biomarker for suicide.
In conclusion, while expression profiling confirmed and further
extended the implication of serotonergic genes in suicide in the
DLPFC, the present study also reveals a significant decrease in
expression of metallothioneins subfamilies1 and 2, a family of
Figure 3. Expression levels in the NACC of six metallothionein genes in as measured by qPCR in psychiatrically normal controls and
mood disorder patients that did (Mood-S) or did not commit suicide (Mood-NS). * denotes significance at the P,0.05 versus the Mood-S
group.
doi:10.1371/journal.pone.0035367.g003
Gene Expression in Suicide Brains
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in suicide victims compared to non-suicide mood disorder patients.
Because cortisol levels are known to be elevated in depressive
states, the observed decreased in MT expression in the suicide
group might point to a failed neuroprotective mechanism against
cortisol in this group and point to a new marker and possible
pharmacological target for suicide and suicidal behavior.
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